Meet our team
Usha Chakravarthy is Professor of Ophthalmology and Vision Sciences in the Queen’s University of Belfast. She has published extensively in the management of retinal disorders and has a varied portfolio of research interests having explored the cell and molecular biology of the retina and its vasculature for many decades. Her work also extends to the epidemiology and risk factors for retinal diseases and her present research is focussed on the relationships between retinal morphology and function based on invivo high resolution imaging and deep functional testing. These in vivo studies also provide fodder for machine learning and gene association investigations . She has delivered many eponymous and other invited lectures in the UK and abroad was honoured in the Queen’s Birthday Honours List with the award of Commander of the British Empire (CBE) for her services to Ophthalmology and voluntary service to managing eye conditions.
In May 2019 Professor Usha Chakravarthy was recognised as a World Expert in Macular Degeneration having been placed in the top 0.1% of scholars writing about Macular Degeneration over the past 10 years.
In addition QUB has been recognised as the second leading institution in the UK for diabetic retinopathy and AMD…
Professor Tunde Peto
Tunde Peto is Professor of Clinical Ophthalmology at Queen’s University Belfast where she is responsible for teaching both undergraduate and postgraduate students. Her remit also covers the development of International image analysis, training and educating in Countries throughout the world.
In addition to her academic work, Professor Peto is also responsible for the Belfast Ophthalmic Image Reading Centre and a wide research portfolio. Her main interest has always been common blinding retinal diseases, with special emphasis on characterisation of diabetic retinopathy and its imaging modalities.
Professor Peto has been involved in UK National Diabetic Retinopathy Screening programmes since 2002, she was clinical lead for London programmes and is currently the clinical lead for the Northern Irish Programme.
Professor Tunde Peto trained in Hungary and Australia and spent 15 years at Moorfields Eye Hospital in London before taking up her current position in Belfast
Professor Nathan Congdon
Prof Nathan Congdon, MD, MPH, is Ulverscroft Chair of Global Eye Health at Queen’s University Belfast and Director of Research for ORBIS International, helping also to shape the organization’s global strategic approach to diabetic eye disease and glaucoma. Prof Congdon is a Visiting Professor at Zhongshan Ophthalmic Center (ZOC) in Guangzhou, and was based there and elsewhere in China for nearly ten years until 2015.
He received an AB degree from Princeton University and an MPhil from Cambridge in the UK, both in Oriental studies, and is fluent in written and spoken Chinese. His medical and public health education were at Johns Hopkins University, where he pursued an ophthalmology residency at the Wilmer Eye Institute.
Prof Congdon’s work has focused on the design and evaluation of high-quality, low-cost models of eye care delivery in areas of limited resources throughout the world, and frequently involves NGOs working together with academic institutions in Asia and the west.
In addition to other recognitions, Prof Congdon has received the Asia Pacific Academy of Ophthalmology’s highest prize for blindness prevention work in 2009 and a Chinese government Thousand Man Plan award in 2011. His research has been supported by the UK government MRC, EU, World Diabetes Foundation, USAID, WHO, World Bank, United States NIH, several NGOs and the governments of China and Hong Kong. He has over 200 peer-reviewed publications in journals including Lancet Global Health, BMJ and JAMA.
Professor Augusto Azuara-Blanco
Research Interests: My academic career is focused in trying to improve eye care and investigating the efficacy, efficiency and safety of new technologies for eye diseases (e.g., treatments, diagnostic tests, models of eye care). I have expertise in primary and secondary research methodology. I am Chief Investigator of several trials, including EAGLE, an international multicentre RCT comparing primary lens extraction versus laser iridotomy in patients with angle-closure glaucoma; GATE, an UK-based multicentre diagnostic study evaluating automated imaging technologies in glaucoma; and CHAMP-UK, a multicentre randomised trial evaluating low dose atropine eye drops for children with myopia. I am co-applicant of several UK-based trials: TAGS and GLAURIOUS (on glaucoma), DIAMONDS and EMERALD (on diabetic retinopathy), EDNA and MIRROR (on age-related macular degeneration). Overall I have raised over £12m of research funds from MRC, NIHR-EME, NIHR-HTA, Horizon 2020, and charities. I have published over 190 peer-reviewed papers, 17 book chapters, and edited three books. My work has been cited over 4000 times and my current Scopus h-index is 37.
Leadership positions: member of the Executive Commitee of the European Glaucoma Society, 2012 Chair of the UK & Eire Glaucoma Society. Member of the Editorial Board of several specialist journals, including the Cochrane Eye and Vision Group, EYE and Journal of Glaucoma. Past member of the Scientific Committee of the Royal College of Ophthalmologists. Examiner for the Royal College of Surgeons of Edinburgh. Past lead of the CCRN-NIHR (Scotland 2010-2012).
Special honours: Recipient of the 2008 American Academy of Ophthalmology achievement award; honorary member of the Italian Glaucoma Society
Dr Ruth Hogg
Dr Hogg's lab is focused on the gollowing themes:
- The epidemiology of age - related eye diseases such as Age - related macular degeneration (AMD), Diabetic Retinopathy and Glaucoma.
- Exploring the utility of new tecnologies for measuring and monitoring visual function including both handheld devices and virtual reality headsets.
- Identifying structural, serological and functional biomarkers of Age-related macular degeneration (AMD) and Diabetic Retinopathy using traditional statistics and machine learning.
- Understanding the differences between normal ocular ageing and the earliest stages of AMD, diabetic retinopathy and glaucoma.